

# Framingham Score Not Aided by CRP Results

BY BRUCE JANCIN

FROM THE ANNUAL SCIENTIFIC SESSIONS  
OF THE AMERICAN HEART ASSOCIATION

CHICAGO – Measurement of high-sensitivity C-reactive protein had little to no utility in refining cardiovascular risk assessment beyond that provided by the classic risk factors in a new secondary analysis of ASCOT, throwing into question the biomarker's appropriate role in clinical practice.

"In the ASCOT-Lipid Lowering Arm, neither baseline nor on-treatment CRP provided any useful information about the efficacy of statin treatment to reduce cardiovascular events beyond LDL cholesterol reduction. These results do not support current proposals to measure CRP in the clinical setting, either to assign statins to individuals on the basis of an elevated CRP alone or to monitor

provided any practical information.

"I think our conclusion is fairly clear: In patients with hypertension, they're on statins. In patients with diabetes, they're on statins. In patients with stable coronary artery disease, they're on statins. There's no added benefit to be gained from measuring CRP," Dr. Sever said.

Discussant Dr. Donald Lloyd-Jones said that "the ASCOT data are the latest

adding to a large body of literature suggesting minimal clinical utility for CRP in risk assessment and decision making for lipid-lowering therapy, and a small, growing, and frankly mixed literature examining the utility of on-treatment CRP levels," observed Dr. Lloyd-Jones, professor of preventive medicine at Northwestern University, Chicago.

In ASCOT, patients with an on-treatment LDL below the median had a re-

duced cardiovascular event risk regardless of their CRP level, while those with a higher LDL had a higher risk regardless of their CRP level. And among patients with a low on-treatment LDL, having a low CRP was not associated with additional benefit, he noted.

Factoring in baseline CRP resulted in a net reclassification improvement score, or NRI, of 0.005 in ASCOT participants at intermediate risk on the basis of their



**'In patients with diabetes, they're on statins. ... There's no added benefit to be gained from measuring CRP.'**

DR. SEVER

CRP levels as an indicator of the efficacy of statin treatment," Dr. Peter S. Sever said at the meeting.

In ASCOT (the Anglo-Scandinavian Cardiac Outcomes Trial), combining a baseline determination of CRP with a standard Framingham Risk Score did not significantly enhance the ability to predict future cardiovascular disease events beyond that provided by Framingham score alone. And, while once patients were on statin therapy, the resultant reduction in LDL was associated with an impressive 55% reduction in cardiovascular events compared with placebo, the decrease in CRP was not linked to a significant decrease in such events, according to Dr. Sever, professor of clinical pharmacology and therapeutics at Imperial College, London.

ASCOT was a landmark primary prevention trial in which nearly 20,000 hypertensive patients were randomized to one of two antihypertensive regimens, then the 10,305 participants with a total cholesterol level of 250 mg/dL or less were re-randomized to 10 mg/day of atorvastatin (Lipitor) or placebo. Although this was a primary prevention trial, these were high-risk patients with three other cardiovascular risk factors in addition to hypertension and a mean 28% risk of developing cardiovascular disease within the next 10 years based upon their Framingham Risk Score.

The new retrospective ASCOT analysis involved 485 patients who experienced a coronary event or stroke during 3.3 years of follow-up and 1,367 controls who did not. Analyzing the data with use of four different statistical methods, neither baseline CRP nor change in CRP level after 6 months of statin therapy

## Easy to teach<sup>1</sup>

— Can be used in 6 straightforward steps

## Easy to use<sup>1</sup>

— Only long-acting insulin pen in which dose can be set from 1 to 80 units in 1-unit steps, dialed both up and down

— Once opened, Lantus® SoloSTAR® can be used for up to 28 days and is not refrigerated

## Easy to inject<sup>1</sup>

— Dose cannot be dialed past the number of units left in the pen

— It is important to keep the injection button pressed all the way in and to **slowly count to 10 before withdrawing the needle from the skin**. After a full injection, the number in the dose window will return to zero. These steps help ensure that the full dose has been delivered

— To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose

## Important Safety Information for Lantus®

### Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

### Warnings and precautions

Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

### Drug interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

### Adverse reactions

Other adverse reactions commonly associated with Lantus® are injection site reaction, lipodystrophy, pruritus, and rash.

## Indications and Usage for Lantus®

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and children (6 years and older) with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

**Important Limitations of Use:** Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Lantus® SoloSTAR® is a disposable prefilled insulin pen.

**Please see brief summary of full prescribing information for Lantus® on the next page.**

**References:** 1. Data on file, sanofi-aventis U.S. LLC. 2. Lantus Prescribing Information. September 2009.

Framingham score. The NRI is a recently developed measure that has been embraced by preventive medicine because it expresses how useful a novel cardiovascular risk factor is in further defining Framingham intermediate-risk patients as either high- or low-risk. The NRI for baseline CRP in ASCOT was weak and nonsignificant. By contrast, the NRI for coronary artery calcium score in Framingham intermediate-risk patients in the Multi-Ethnic Study of Atherosclerosis (MESA) was a robust 0.55, more than two orders of magnitude greater than for CRP in ASCOT.

ASCOT is just the latest in a growing number of studies that raise a central



**ASCOT is just the latest of several studies that ask, 'Is CRP something we need to be spending our time on?'**

DR. LLOYD-JONES

question, he added: "Is CRP something we need to be spending our time on?"

So how often does Dr. Lloyd-Jones obtain a CRP in his own clinical practice? "Never," he said in an interview.

Asked to comment, Dr. Christopher Cannon of Brigham and Women's Hospital, Boston, said his interpretation of the ASCOT results is that in patients who already have a good indication for statin therapy, knowing the baseline CRP level does not provide additional useful information.

"Once you get into places where you should be treating anyway, then CRP is not helpful. But in the JUPITER trial they had patients largely without other

risk factors, and in that lower-risk group a high baseline CRP picked out those who would benefit from statin therapy," Dr. Cannon explained.

He agreed with Dr. Sever and Dr. Lloyd-Jones that the message from ASCOT regarding the use of on-treatment CRP to titrate statin therapy is that it doesn't make sense.

Dr. Sever declared that he is a consultant to and is on the speakers bureau for Pfizer, which sponsored ASCOT. Dr. Cannon is also on the speakers bureau for Pfizer. Dr. Lloyd-Jones reported no relevant financial interests. ■

For patients with diabetes using an insulin vial and syringe

## Take aim with the Lantus® SoloSTAR® pen

**Delivers 50% more insulin units per prescription for the same co-pay as a vial and syringe on most insurance plans**

**Prefilled with Lantus®, the only 24-hour insulin approved exclusively for use once a day to help patients with diabetes aim toward glycemic control<sup>2</sup>**

Once-Daily  
24-HOUR

**LANTUS® SoloSTAR®**  
insulin glargine [rDNA origin] injection

**STARring the #1-prescribed insulin<sup>a</sup>**

<sup>a</sup>Based on TRx data from IMS Health, NPA™  
Monthly database, time period from May 2003 to March 2010.

**sanofi aventis**  
Because health matters

© 2010 sanofi-aventis U.S. LLC

US.GLA.10.05.140